September 2016

A Step Backward: HRSA’s Elimination of the ACHDNC Threatens Progress on Newborn Screening

Author: NCMVF Board of Directors The National CMV Foundation is deeply concerned by HRSA’s recent decision to dissolve the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)—a cornerstone of equitable, evidence-based newborn screening for over 20 years. Without this federal oversight, there's now no national process to evaluate and recommend new conditions—including congenital cytomegalovirus (CMV), the most common infectious cause of birth defects and developmental disabilities in the U.S.

CMV Public Health & Policy Conference Roundup - Part One

This week saw the conclusion of the 2nd CMV Public Health & Policy Conference in Austin, Texas. This conference’s goals were focused around presenting the latest in CMV prevention, diagnostic, and treatment research, while providing information to attendees about early intervention options and other family and professional support resources. 

After a pregnant friend's CMV diagnosis, a pediatrician takes action

National CMV recently had the chance to speak with Dr. Keren Shahar-Nissan, a pediatrician at Schneider Medical Center of Israel, who has launched a Valacyclovir study in the wake of a friend being diagnosed with CMV infection during her pregnancy. With limited funding and increasing enrollment, Dr. Shahar-Nissan, is hoping for an increased appreciation and enthusiasm towards the prevention of congenital CMV infection.